Thursday, October 15, 2026

Macroeconomics

3 articles

Bond Yield Surge and Fed Leadership Transition Compound Macro Risk in Mid-2026

Bond Yield Surge and Fed Leadership Transition Compound Macro Risk in Mid-2026

Sovereign bond yields across the US, UK, and Japan surged in mid-May 2026 as Jerome Powell's Fed chairmanship expired, stripping global monetary policy of institutional continuity. Services inflation remains above 3% annually and the Iran war added $857 to average American gasoline costs in 2026. AI investment has already surpassed dot-com-era levels as a share of GDP, yet no measurable productivity offset has emerged.

LM Salvado•
Hormuz Blockade Removes 20 Million Barrels Daily, Largest Oil Disruption on Record

Hormuz Blockade Removes 20 Million Barrels Daily, Largest Oil Disruption on Record

The US-Iran conflict has cut 20 million barrels per day from global oil markets through the Hormuz blockade, marking the largest supply disruption ever measured. WTI crude has surged amid extreme volatility, while analysts warn sustained high energy prices could trigger reflationary pressures that threaten economic growth already facing tariff headwinds.

ViaNews Editorial Team (Finance)•
Dollar Hits Three-Year Low as Fed Transition and Iran Deal Progress Shift Currency Markets

Dollar Hits Three-Year Low as Fed Transition and Iran Deal Progress Shift Currency Markets

The US dollar fell to its lowest level since 2022 against major currencies as geopolitical tensions eased and markets anticipated Federal Reserve leadership changes. The British pound dropped 0.4% to €1.13, its weakest since April 2023, while safe-haven currencies like the Swiss franc gained ground. Currency analysts forecast further pound weakness ahead of the UK's November 26 budget.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com